PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
11.46 USD   -2.13%
08/04PROTAGONIST THERAPEUTICS : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/04PROTAGONIST THERAPEUTICS : Q2 Earnings Snapshot
AQ
08/04PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to Russell 3000E Value Index

06/24/2022 | 12:00am EDT

Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to Russell 3000E Value Index


© S&P Capital IQ 2022
All news about PROTAGONIST THERAPEUTICS, INC.
08/04PROTAGONIST THERAPEUTICS : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/04PROTAGONIST THERAPEUTICS : Q2 Earnings Snapshot
AQ
08/04PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
08/04Protagonist Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six ..
CI
08/04PROTAGONIST THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Provides Corp..
PU
07/19Protagonist Therapeutics Reports Granting of Inducement Award
PR
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 3000 Growth Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell Microcap Value Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 2000 Growth Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell 2000 Value Index
CI
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 36,0 M - -
Net income 2022 -153 M - -
Net cash 2022 174 M - -
P/E ratio 2022 -3,88x
Yield 2022 -
Capitalization 563 M 563 M -
EV / Sales 2022 10,8x
EV / Sales 2023 47,1x
Nbr of Employees 127
Free-Float 98,6%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 11,46 $
Average target price 40,00 $
Spread / Average Target 249%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Asif Ali Chief Financial Officer & Executive Vice President
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Research & Development Strategy Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.-66.49%563
MODERNA, INC.-26.44%73 092
IQVIA HOLDINGS INC.-16.94%43 781
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235